Atorvastatin in combination with conventional antimicrobial treatment of Helicobacter pylori eradication: A randomized controlled clinical trial.

Abstract

Helicobacter pylori is one of the main causes of digestive diseases, which is difficult to treat and requires the administration of several antimicrobial agents. Considering the anti-inflammatory and antibacterial effect of atorvastatin, the present study aimed at adding this agent to a four-drug regimen in order to eradicate H.pylori. A total of 220 patients with H.pylori infection were included in the current randomized controlled clinical trial. In the current study, 110 patients in the control group received a 14-day regimen of amoxicillin, clarithromycin, bismuth, and esomeprazole, and 110 patients in the intervention group received 40mg of atorvastatin daily plus the antibiotic regimen for 14weeks. The treatment results were evaluated 1month later using H.pylori stool antigen test. Data were collected using checklist and analyzed using chi-squared and Fisher's exact tests with spss version 18. Helicobacter pylori eradication rate in the intervention and control groups was 78.18% and 65.45%, respectively (P=0.025), and there was a significant difference in terms of non-ulcer dyspepsia between the groups (P=0.049), but there was no significant difference in age, gender, and body mass index between the two groups (P<0.05). The present study results showed that adding atorvastatin to the four-drug regimen of omeprazole, clarithromycin, bismuth, and amoxicillin is effective in the eradication of H.pylori. Also, the addition of atorvastatin to H.pylori eradication therapy is more effective in patients with non-ulcer dyspepsia.